CARDIOVASCULAR RISK ASSESSMENT IN RHEUMATOID ARTHRITIS WITH NODULOSIS: APPROACH TO PRIMARY PREVENTION
| Autor: | Dinu Valentin Balanescu, Cristina Ileana Iosif, Andra Rodica Balanescu, Ruxandra Ionescu, Denisa Predeteanu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Romanian Journal of Rheumatology, Vol 28, Iss 1, Pp 30-35 (2019) |
| Druh dokumentu: | article |
| ISSN: | 1843-0791 2069-6086 |
| DOI: | 10.37897/RJR.2019.1.6 |
| Popis: | Cardiovascular risk assessment in patients with rheumatoid arthritis (RA) is challenging. Not all risk calculators adjust for RA status, yielding discording results. A 56-year-old woman with RA presented for bilateral pain and swelling in the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints. She was diagnosed with RA 10 years ago, currently treated with methotrexate (MTX), sulfasalazine, and hydroxychloroquine. She has a history of type 2 diabetes mellitus, a total abdominal hysterectomy with bilateral salpingo-oophorectomy for an epidermoid carcinoma of the cervix, and surgical excision of a pulmonary rheumatoid nodule. Multiple subcutaneous nodules are seen bilaterally on the MCP and PIP joints. MTX may be associated with nodulosis in RA patients, which in turn is related to a further increase in cardiovascular risk compared to RA alone. MTX was discontinued. Abatacept was the biologic of choice, due to recent evidence suggesting superior efficacy in decreasing cardiovascular risk compared to anti-TNF therapies, especially in patients with diabetes and with positive rheumatoid factor. Initiating high-dose statin and abatacept may be a useful primary prevention strategy in complex RA patients that require biologic therapy.. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|